An interventional study of Equia Forte Fil and Zirconomer Improved in Dental Caries, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 47 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-17.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
This study is conducted to evaluate the clinical performance of class I reinforced glass ionomer restorations (Zirconomer Improved and Equia Forte Fil)
1,107 studies on the registry are indexed under Dental Caries; 197 are open to participants now.
This study's enrollment of 20 is below the median of 60 across 915 interventional studies indexed under Dental Caries.
Browse Dental Caries studies →Al-Azhar University is the lead sponsor of 505 studies on the registry; 167 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Equia Forte Fil · Other: Zirconomer Improved
Other: Equia Forte Fil · Other: Zirconomer Improved
Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
Clinical Performance of the restoration
Success Rate
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al-Azhar University